Jaime Gállego Pérez -Larraya

Health Research Institute of Navarra (IdiSNA), Program in Solid Tumors, Foundation for the Applied Medical Research, Department of Neurology, Clinica Universidad de Navarra, Pamplona, Navarra, Spain
Pamplona, Navarra, Spain

Dr. Jaime Gállego Pérez-Larraya studied medicine at the University of Navarra, Pamplona, Spain. Afterwards he completed his residency training program in Neurology at the Clinic of the University of Navarra, and then became faculty at the Department of Neurology of the same institution. He focused his clinical interest in the management of patients with primary brain tumours and neurological complications of cancer, which brought him to perform a clinical fellowship in Neuro-Oncology at the Hôpital La Salpêtrière, in Paris (France). He was involved in clinical trials for patients with glioblastoma and centered his translational research on circulating biomarkers for gliomas. In 2011 he joined back as coordinator the Division of Neuro-Oncology at the University of Navarra, and obtained his PhD in 2013. Over the past years immunovirotherapy for both adult and pediatric patients with malignant gliomas has become a major topic of clinical research. He is an active member of the European Association of Neuro-oncology (EANO) and Brain Tumor Group of the European Organisation for the Research and Treatment of Cancer (EORTC), where he has integrated the Scientific Committee and the Neuroimaging Committee, respectively. He has also coordinated the Neuro-Oncology Study Group of the Spanish Society of Neurology (SEN) and is currently the spanish representant of the Scientific Panel of Neuro-Oncology of the European Association of Neurology (EAN). From a practical point of view, Dr. Gállego Pérez-Larraya has participated in variuos research projects and international clinical trials for patients with brain tumors, and has also led the development of investigator-initiated clinical trials of virotherapy for adult and pediatric patients with gliomas. His main research interests are circulating biomarkers for glioblastoma and the development of novel immunovirotherapy strategies for both adults and children with diffuse gliomas.